The homologous proteins MDM2 and MDMX negatively regulate the tumor suppressor protein p53 by antagonizing p53 transactivation activity and targeting p53 for degradation. MDM2 and MDMX bind to p53 via N-terminal p53-binding domains to control the level of p53. The N-terminal regions of MDM2 and MDMX are modified in vivo under stressed conditions, suggesting that modifications to MDM2/MDMX also may affect the p53-MDM2/MDMX interaction. Ample evidence suggests that the MDM2 lid (residues 1-24) is partially structured and significantly reduces its binding affinity with p53 several fold. Since MDM2 and MDMX possess very similar p53-binding domains but different lids, however, the function of the N-terminal lid of MDMX still remains poorly understood. Using a native chemical ligation technique, the p53-binding domain of MDMX, (1-108)MDMX, and its N-terminal lid (residues 1-23) truncated analogue (24-108)MDMX were chemically synthesized. We comparatively characterized their structures by circular dichroism (CD) spectra, and measured their binding affinities with a panel of p53-derived peptide ligands by fluorescence polarization and surface plasmon resonance assays. Our results indicate that, as opposed to the lid of MDM2, the lid of MDMX has little effect on p53-binding, adopts no structural conformation, and has rare auto-inhibitory function. Different lid modifications of MDM2 and MDMX are functionally different with respect to p53 binding, which should be considered when designing dual specific inhibitors of MDM2 and MDMX.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1248/cpb.c15-00975 | DOI Listing |
J Am Chem Soc
December 2024
Department of Systems Biology, School of Life Sciences, Southern University of Science and Technology, Shenzhen 518055, China.
PROTACs have emerged as a therapeutic modality for the targeted degradation of proteins of interest (POIs). Central to PROTAC technology are the E3 ligase recruiters, yet only a few of them have been identified due to the lack of ligandable pockets in ligases, especially among single-subunit ligases. We propose that binders of partner proteins of single-subunit ligases could be repurposed as new ligase recruiters.
View Article and Find Full Text PDFCell Oncol (Dordr)
December 2024
Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, 625 00, Czech Republic.
Purpose: Pediatric sarcomas are bone and soft tissue tumors that often exhibit high metastatic potential and refractory stem-like phenotypes, resulting in poor outcomes. Aggressive sarcomas frequently harbor a disrupted p53 pathway. However, whether pediatric sarcoma stemness is associated with abrogated p53 function and might be attenuated via p53 reactivation remains unclear.
View Article and Find Full Text PDFSmall
November 2024
Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.
The treatment of retinoblastoma (RB), a formidable eye cancer that affects infants and children, is not only aimed at saving lives but at preserving ocular function, maintaining optimal visual acuity, and enhancing the overall quality of life. Photodynamic therapy has already been established as a secure and dependable therapeutic modality for the treatment of ocular diseases that effectively preserves ocular function; however, it fails to provide satisfactory outcomes against RB. To address this formidable challenge, groundbreaking advancement is aspired by delving into the genetic characteristics of RB, which initially involves the wild-type p53 pathway but is subsequently suppressed by MDM2 and MDMX.
View Article and Find Full Text PDFExpert Opin Ther Pat
December 2024
Institute of Molecular and Industrial Biotechnology, Lodz University of Technology, Lodz, Poland.
Cells
September 2024
CRBM, Cell Biology Research Centre of Montpellier, Université de Montpellier, CNRS, 34293 Montpellier, France.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!